Barry J. Margulies

Associate Professor


Contact Information

Smith Hall, Room No. 485B
Tuesday & Thursday 1230-130pm Wednesday 2-3pm


S.B Massachusetts Institute of Technology, Applied Biological Sciences
PhD Johns Hopkins University School of Medicine, Biochemistry, Cell, and Molecular Biology
Post-doc Johns Hopkins University School of Medicine, Comparative Medicine

Areas of Expertise

Molecular virology
Antimicrobial pharmacology
Controlled release technology


Current antiviral therapy for the human herpes viruses, HSV–1, –2, and varicella zoster virus and the feline herpesvirus, FHV-1, consists of multiple doses of FDA-approved anti-herpetic drugs (typically acyclovir [ACV], valacyclovir, penciclovir [PCV], or famciclovir) taken daily for the lifetime of the host. These daily doses require rigorous patient compliance; missed doses allow small windows of drug troughs that permit breakout replication, sometimes resulting in drug-resistant mutants. Our research involves slow, controlled release of ACV or PCV from both biodegradable and non-biodegradable polymer matrices. These devices release continuous, steady levels of drug for an estimated 3 to 5 years after a single implantation. We are continuing to explore the chemistry, biology, pharmacology, and engineering of these implants to further improve their design and eventual clinical deployment in human and veterinary patients.


Patents Pending

  • T.P. Johnson and B.J. Margulies. Long-Term Suppression of Herpesvirus Infection (provisional #60805381, 2006; pending #11/766,298, 2007)
  • B.J. Margulies, J.K. Badin, Fartash-Naini, S., T. Etienne, S. Fargis, A. Samra. Biodegradable Subcutaneous Implants and Method of Making (pending #14/199,010, 2014)


  • Margulies, B.J. and C.A. Ghent. Alternative Assessment Strategy and Its Impact on Student Comprehension in an Undergraduate Microbiology Course. Microbiology Education. 6:3-7 (2005).
  • Margulies, B.J., and W. Gibson. The Chemokine Receptor Homologue Encoded by US27 of Human Cytomegalovirus is Heavily Glycosylated and Is Present in Infected Human Foreskin Fibroblasts and Enveloped Virus Particles. Virus Res 123:57-71 (2007).
  • Johnson, T.P,. Frey, R., Modugno, M., Brennan, T.P., and B.J. Margulies. Development of an Acyclovir Implant for the Long-Term Control of Herpes Simplex Virus Infection. Int J Antimicrob Agents 30:428-435 (2007).
  • Berkower, C.L., Johnson, N.M., Longdo, S.L., McGusty-Robinson, S.O., Semenkow, S.L., and B.J. Margulies. Silicone-Acyclovir Controlled Release Devices Suppress Primary Herpes Simplex Virus-2 and Varicella Zoster Virus Infections In Vitro. Adv Pharmacol Sci 2013:915159 (2013).
  • Semenkow, S.L., Johnson, N.M., Maggs, D.J., and B.J. Margulies. Controlled Release Delivery of Penciclovir via a Silicone (MED-4750) Polymer: Kinetics of Drug Delivery and Efficacy in Preventing Primary Feline Herpesvirus Infection in Culture. Virology J 11:34 (2014).

Courses Taught

  • BIOL 201 Introduction to Cell Biology and Genetics
  • BIOL 428 / 528 Virology
  • BIOL 420 Microbiology of Infectious Disease
  • BIOL 622 Gene Expression and Regulation